Tobramycin inhalation solution - Novartis

Drug Profile

Tobramycin inhalation solution - Novartis

Alternative Names: TOBI; TOBI NextGen; Tobramycin aerosol - Chiron

Latest Information Update: 31 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novartis
  • Class Aminoglycosides; Antibacterials; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis-associated respiratory tract infections
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cystic fibrosis-associated respiratory tract infections
  • Discontinued Bronchiectasis; Respiratory tract infections; Tuberculosis

Most Recent Events

  • 31 Jul 2017 Discontinued - Phase-III for Cystic fibrosis-associated respiratory tract infections (In infants, In children) in Romania, Egypt, Poland, Italy, Germany, Greece, France, Russia, Switzerland, Hungary and Canada (Inhalation), because not listed on Novartis pipeline, December 2016
  • 15 Mar 2016 Biomarkers information updated
  • 14 Apr 2015 Novartis completes enrolment in the phase III EARLY trial for Cystic fibrosis-associated respiratory tract infections (In infants, In children) in Canada, Hungary, Egypt, France, Germany, Greece, Italy, Poland, Romania, Russia and Switzerland (NCT01082367)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top